CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer
CERo Therapeutics Holdings, Inc. (CERO)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces key appointments to the Company’s management team to support recently named interim CEO, Chris Ehrlich. Andrew Albert “Al” Kucharchuk has been named Chief Financial Officer and Kristen Pierce, Ph.D., has been appointed Chief Development Officer. “I believe we have the team in place to successfully drive CERo forward into the clinic and to create the Company we have promised our shareholders. These new management team members are seasoned professionals with extensive experience in early drug development and the capital markets. I want to take this opportunity to thank Brian Atwood for his service as CEO, and appreciate his continued service on our Board of Directors. Further, I am very excited to begin to col
Show less
Read more
Impact Snapshot
Event Time:
CERO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERO alerts
High impacting CERo Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERO
News
- CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous LeukemiaGlobeNewswire
- CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without ToxicityGlobeNewswire
- CERo Therapeutics files to sell 713.6M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- CERo Therapeutics, Inc. Provides Corporate UpdateGlobeNewswire
- CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 [Yahoo! Finance]Yahoo! Finance
CERO
Sec Filings
- 11/20/24 - Form 424B3
- 11/20/24 - Form 424B3
- 11/20/24 - Form SC
- CERO's page on the SEC website